Australian Market Report of September 2, 2010: Tanami Gold High Grade Results at Central Tanami Project
Perth based base metals explorer Empire Resources Limited (ASX:ERL) (PINK: ERSO) has entered into an option agreement to purchase an interest in three granted exploration licences and two granted prospecting licences held by La Mancha Resources Australia surrounding the Company's advanced Yuinmery copper - gold resource project in Western Australia. The five tenements are the subject of a joint venture between La Mancha Resources Australia and Giralia Resources Limited (ASX: GIR) in which La Mancha currently holds an interest of approximately 75.82%. Under the terms of the option agreement, Empire must spend a minimum of A$150,000 per annum for up to three years while retaining an option to purchase La Mancha's interest for a cash consideration of A$750,000.
The signing yesterday in Port Augusta of a Native Title Mining Agreement has opened the way for the development of IronClad Mining Limited's (ASX: IFE) Wilcherry Hill iron ore project on Eyre Peninsula, South Australia. The Native Title Mining Agreement provides a range of measures and opportunities that will flow from the development of a mining operation at Wilcherry Hill in a manner sensitive to Aboriginal cultural and heritage issues. Development of the Wilcherry Hill iron ore project, 120 kilometres west of Whyalla, is scheduled to begin production with Stage 1 commencing next year. It will be one of the first iron ore export operations in the world to ship high quality, high grade crystalline magnetite as Direct Shipping Ore (DSO).
HealthLinx Limited (ASX:HTX) has finalised research agreements with its collaborators in South Korea to begin the 220 patient study required for South Korea Food and Drug Administration (KFDA) approval for the distribution of OvPlex(TM). The trial will be conducted by Principal Investigator Professor Byoung-Gie Kim of Samsung Medical Center and Sungkyunkwan (SKK) University School of Medicine. Professor Kim assisted HealthLinx in securing further key institutions to participate in the trial including the highly reputable Asan Medical Centre and Seoul National University Hospital. Collectively the three hospitals have over 12,000 beds and support the three leading gynaecological cancer research centres in the country.
Contact:
Asia Business News (ABN Newswire)
Tel: +61-2-9247-4344
Fax: +61-2-9225-9034
www.abnnewswire.net